⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTXR News
Citius Pharmaceuticals Inc. Common
BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics
globenewswire.com
NVS
CGNX
FBIO
CTXR
Form 8-K
sec.gov
CTXR
Form 8-K
sec.gov
CTXR
CTOR
Form 8-K
sec.gov
CTOR
CTXR
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
prnewswire.com
CTXR
CTOR
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
prnewswire.com
CTXR
CTOR
Centri Announces Participating Companies for Second Annual Capital Conference at Nasdaq
accessnewswire.com
ATYR
CTXR
MVBF
Form 8-K
sec.gov
CTXR
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTXR